Agile Therapeutics Inc (AGRX)

[beambe]

from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $4.



In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $4. The company’s shares closed yesterday at $1.02, close to its 52-week low of $0.23.

Livnat commented:

“We expect that meeting will happen by late- November or early-December. Assuming no negative surprises, like an unfeasible non-inferiority margin requirement vs. Xulane, we’d expect Agile could commence dosing by early-January 2019 at the latest. Note that Agile, per an 8-K filing, already entered a clinical research agreement with TKL Research, a specialist dermatology-focused CRO, to potentially conduct the wear study. Again, barring unexpected study complexity, we see no reason why a study couldn’t be very quickly completed, with typical single-arm studies lasting just a week, so this two-arm study likely just two weeks. Assuming acceptable adhesion, we could see an NDA filing by early-2Q19, followed by a likely Advisory Committee meeting to assess Twirla’s efficacy profile.”

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 6.7% and a 59.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Jazz Pharmaceuticals, and Cara Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agile Therapeutics with a $4 average price target.

https://www.smarteranalyst.com/brief/analysts-offer-insights-on-healthcare-companies-immunogen-imgn-agile-therapeutics-agrx-and-aveo-pharma-aveo/